MedTrace Logo

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

NCT07019844 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-07-23

No results posted yet for this study

Summary

This prospective, single-center study evaluates the clinical utility of F18-Piflufolastat (PSMA) PET/CT when added to conventional cross-sectional imaging for patients with suspected or confirmed hepatocellular carcinoma (HCC). The study aims to determine whether PSMA PET/CT improves diagnostic accuracy for indeterminate liver lesions (LI-RADS 3 and 4), enhances staging precision in treatment-naïve patients, and provides more accurate assessment of treatment response in patients undergoing locoregional therapy (LRT). The goal is to assess how PSMA PET/CT may impact clinical decision-making, staging, and management of HCC across multiple stages of disease.

Conditions

  • Hepatocellular Carcinoma (HCC)

Sponsors & Collaborators

  • Miami VA Healthcare System

    collaborator FED

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Binu V John, MD MPH · Miami VA Healthcare System, Miami, FL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2027-12-30
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07019844 on ClinicalTrials.gov